Aripiprazole induced Parkinsonism: A case report;Syndrome parkinsonien sous aripiprazole : à propos d'un cas

Encephale

Volumn 35, Issue 5, 2009, Pages 496-498

  Pasquier de Franclieu, S ^a   Germain, C ^a   Petitjean, F ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Aripiprazole; Cytochrome P450; Parkinsonian symptoms; Psychosis

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; HALOPERIDOL; OLANZAPINE; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AKINESIA; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GAIT DISORDER; HUMAN; HYPERSALIVATION; MUSCLE HYPERTONIA; PARANOID SCHIZOPHRENIA; PARKINSONISM; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; PSYCHOLOGICAL ASPECT;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; PARKINSONIAN DISORDERS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA, PARANOID;

EID: 71349086593     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2008.06.019     Document Type: Article

References (16)

1. Burris K.D., Molski T.F., Xu C., et al. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 (2002) 381-389
2. Callaghan J.T., Bergstrom R.F., Ptak L.R., et al. Olanzapine. Pharmacocinetic and pharmacodynamic profile. Clin Pharmacokinet 37 (1999) 177-193
3. Cohen S.T., Rulf D., and Pies R. Extrapyramidal side effects associated with aripiprazole coprescription in two patients. J Clin Psychiatry 66 (2005) 135-136
4. Frenckell R. Impressions cliniques globales CGI. Évaluation clinique standardisée en psychiatrie. Tome 1 (1996), Éditions médicales Pierre-Fabre, Castres Sous la direction de JD Guelfi
5. Harrison T.S., and Perry C.M. Aripiprazole: a review of its use in schizophrenia and affective disorder. Drugs 64 (2004) 1715-1736
6. Huang M., Van Peer A., Woestenborghs R., et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54 (1993) 257-268
7. Jordan S., Koprivica V., Chen R., et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441 (2002) 137-140
8. Kane J.M., Carson W.H., Sara A.R., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63 (2002) 763-777
9. Lindsey R.L., Kaplan D., Koliatsos V., et al. Aripiprazole and extrapyramidal symptoms. J Am Acad Child Adolesc Psychiatry 42 (2003) 1268-1269
10. McQuade R., Burris K.D., Jordan S., et al. Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharm 5 (2002) S176
11. Brahm N.C., McElwain D.L., and Brown R.C. Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. Am J Health Syst Pharm 64 (2007) 827-829 15
12. Salmoiraghi A., and Odiyoor M. A case of aripiprazole and extrapyramidal side effects. J Psychopharmacol 20 (2006) 592-593
13. Schillevoort I., de Boer A., van der Weide J., et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 12 (2002) 235-240
14. Schonberger R.B., Douglas L., and Baum C.R. Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole. Pediatrics 114 (2004) 1743
15. Sharma A., and Sorrel J.H. Aripiprazole-induced parkinsonism. Int Clin Psychopharmacol 21 (2006) 127-129
16. Ziegenbein M., Sieberer M., Calliess, et al. Aripiprazole-induced extrapyramidal side effects in a patient with schizoaffective disorder. Aust N Z J Psychiatry 40 (2006) 194-195